Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company expects the full year’s revenue to be around $14.75 billion, close to analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15% above analysts’ consensus estimates.
Is now the time to buy Viatris? Find out by accessing our full research report, it’s free.
Viatris (VTRS) Q2 CY2026 Highlights:
- Revenue: $3.76 billion vs analyst estimates of $3.68 billion (4.9% year-on-year growth, 2.2% beat)
- Adjusted EPS: $0.69 vs analyst estimates of $0.60 (15% beat)
- Adjusted EBITDA: $1.19 billion vs analyst estimates of $1.08 billion (31.6% margin, 10.3% beat)
- The company slightly lifted its revenue guidance for the full year to $14.75 billion at the midpoint from $14.7 billion
- Management raised its full-year Adjusted EPS guidance to $2.52 at the midpoint, a 5% increase
- EBITDA guidance for the full year is $4.4 billion at the midpoint, in line with analyst expectations
- Operating Margin: 0.2%, down from 6.5% in the same quarter last year
- Free Cash Flow Margin: 8.8%, up from 4.7% in the same quarter last year
- Market Capitalization: $20.55 billion
Company Overview
Created through the 2020 merger of Mylan and Pfizer's Upjohn division, Viatris (NASDAQ:VTRS) is a healthcare company that develops, manufactures, and distributes branded and generic medicines across more than 165 countries worldwide.
Revenue Growth
A company’s long-term sales performance is one signal of its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Viatris’s demand was weak over the last five years as its sales fell at a 1.1% annual rate. This wasn’t a great result and is a sign of poor business quality.
Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Viatris’s annualized revenue declines of 1.7% over the last two years align with its five-year trend, suggesting its demand has consistently shrunk. 
This quarter, Viatris reported modest year-on-year revenue growth of 4.9% but beat Wall Street’s estimates by 2.2%.
Looking ahead, sell-side analysts expect revenue to grow 1.6% over the next 12 months. While this projection suggests its newer products and services will fuel better top-line performance, it is still below the sector average.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
Adjusted Operating Margin
Viatris has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average adjusted operating margin of 28.7%.
Looking at the trend in its profitability, Viatris’s adjusted operating margin decreased by 14.6 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 9.5 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn’t pass those costs onto its customers.
This quarter, Viatris’s breakeven margin was 0.2%, down 27.5 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.
Earnings Per Share
Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions.
Sadly for Viatris, its EPS declined by 8% annually over the last five years, more than its revenue. This tells us the company struggled because its fixed cost base made it difficult to adjust to shrinking demand.
We can take a deeper look into Viatris’s earnings to better understand the drivers of its performance. As we mentioned earlier, Viatris’s adjusted operating margin declined by 14.6 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.
In Q2, Viatris reported adjusted EPS of $0.69, up from $0.62 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Viatris’s full-year EPS to stay about the same, moving from $2.52 to $2.50.
Key Takeaways from Viatris’s Q2 Results
We enjoyed seeing Viatris beat analysts’ full-year EPS guidance expectations this quarter. We were also glad its EPS outperformed Wall Street’s estimates. Overall, we think this was still a solid quarter with some key areas of upside. The stock traded up 1% to $17.84 immediately after reporting.
Viatris put up rock-solid earnings, but one quarter doesn’t necessarily make the stock a buy. Let’s see if this is a good investment. If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here (it’s free).